{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:01:12Z","timestamp":1773403272872,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007605","name":"Aarhus Universitet","doi-asserted-by":"publisher","award":["1591 8355"],"award-info":[{"award-number":["1591 8355"]}],"id":[{"id":"10.13039\/100007605","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.msard.2021.102879","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T11:42:33Z","timestamp":1615117353000},"page":"102879","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Population-based head-to-head comparison of the clinical characteristics and epidemiology of AQP4 antibody-positive NMOSD between two European countries"],"prefix":"10.1016","volume":"51","author":[{"given":"Papp","family":"Viktoria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim D.P.","family":"Trones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda","family":"Magyari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Koch-Henriksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5442-0794","authenticated-orcid":false,"given":"Anna","family":"Iljicsov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0252-4778","authenticated-orcid":false,"given":"Cecilia","family":"Rajda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helle H.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabor","family":"Lovas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Csilla","family":"Rozsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f8rn H.","family":"Kristiansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egon","family":"Stenager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1661-7438","authenticated-orcid":false,"given":"Jette L.","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Komoly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1333-9623","authenticated-orcid":false,"given":"Finn","family":"Sellebjerg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thor","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"Illes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.102879_bib0001","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102879_bib0002","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102879_bib0003","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","article-title":"What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients","volume":"264","author":"Hamid","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.msard.2021.102879_bib0004","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00415-015-7952-8","article-title":"Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO\/MS overlap syndromes","volume":"263","author":"Jury\u0144czyk","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.msard.2021.102879_bib0005","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.msard.2021.102879_bib0006","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.msard.2018.11.031","article-title":"Clinical characteristics of 153 Brazilian patients with neuromyelitis optica spectrum disorder (NMOSD)","volume":"27","author":"Fragoso","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2021.102879_bib0007","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jneuroim.2016.02.006","article-title":"Increased occurrence of anti-AQP4 seropositivity and unique HLA Class II associations with neuromyelitis optica (NMO), among Muslim Arabs in Israel","volume":"293","author":"Brill","year":"2016","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.msard.2021.102879_bib0008","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1212\/NXI.0000000000000468","article-title":"Mortality in neuromyelitis optica is strongly associated with African ancestry","volume":"5","author":"Mealy","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.msard.2021.102879_bib0009","first-page":"379","article-title":"Ethnic Differences in Clinical Manifestation of Neuromyelitis Optica Spectrum Disorder","volume":"24","author":"Kim","year":"2018","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2021.102879_bib0010","doi-asserted-by":"crossref","first-page":"13706","DOI":"10.1038\/s41598-020-69224-3","article-title":"Native American ancestry significantly contributes to neuromyelitis optica susceptibility in the admixed Mexican population","volume":"10","author":"Hidalgo","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.msard.2021.102879_bib0011","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1038\/s41467-018-04332-3","article-title":"A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica","volume":"9","author":"Estrada","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.msard.2021.102879_bib0012","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/jnnp-2016-314839","article-title":"Incidence and prevalence of NMOSD in Australia and New Zealand","volume":"88","author":"Bukhari","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.msard.2021.102879_bib0013","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.msard.2021.102879_bib0014","doi-asserted-by":"crossref","first-page":"e2265","DOI":"10.1212\/WNL.0000000000006645","article-title":"Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark","volume":"91","author":"Papp","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102879_bib0015","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1007\/s00415-013-6926-y","article-title":"The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom","volume":"260","author":"Jacob","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.msard.2021.102879_bib0016","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1177\/1352458517735191","article-title":"Epidemiology of NMOSD in Catalonia: influence of the new 2015 criteria in incidence and prevalence estimates","volume":"24","author":"Sep\u00falveda","year":"2018","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2021.102879_bib0017","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/jnnp-2017-317321","article-title":"Nationwide epidemiological study of neuromyelitis optica in Japan","volume":"89","author":"Miyamoto","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.msard.2021.102879_bib0018","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.msard.2017.10.015","article-title":"Prevalence of neuromyelitis optica spectrum disorder in the multi-ethnic Penang Island, Malaysia, and a review of worldwide prevalence","volume":"19","author":"Hor","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2021.102879_bib0019","doi-asserted-by":"crossref","first-page":"e79649","DOI":"10.1371\/journal.pone.0079649","article-title":"Neuromyelitis Optica in Austria in 2011: to Bridge the Gap between Neuroepidemiological Research and Practice in a Study Population of 8.4 Million People","volume":"8","author":"Aboul-Enein","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.msard.2021.102879_bib0020","article-title":"Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK","volume":"0","author":"O'Connell","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.msard.2021.102879_bib0021","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/ene.14079","article-title":"A population-based epidemiological study of neuromyelitis optica spectrum disorder in Hungary","volume":"27","author":"Papp","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.msard.2021.102879_bib0022","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1534\/genetics.116.189241","article-title":"Nationwide genomic study in Denmark reveals remarkable population homogeneity","volume":"204","author":"Athanasiadis","year":"2016","journal-title":"Genetics"},{"key":"10.1016\/j.msard.2021.102879_bib0023","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/ajpa.20984","article-title":"A Y-chromosomal comparison of the Madjars (Kazakhstan) and the Magyars (Hungary)","volume":"139","author":"B\u00edr\u00f3","year":"2009","journal-title":"Am J Phys Anthropol"},{"key":"10.1016\/j.msard.2021.102879_bib0024","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1126\/science.1243518","article-title":"A Genetic Atlas of Human Admixture History","volume":"343","author":"Hellenthal","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.msard.2021.102879_bib0025","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1136\/jnnp-2015-312601","article-title":"Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica","volume":"87","author":"Waters","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.msard.2021.102879_bib0026","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1177\/1352458516671203","article-title":"Influence of female sex and fertile age on neuromyelitis optica spectrum disorders","volume":"23","author":"Borisow","year":"2017","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2021.102879_bib0027","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1212\/WNL.0000000000007746","article-title":"Epidemiology of NMOSD in Sweden from 1987 to 2013","volume":"93","author":"Jonsson","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102879_bib0028","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","article-title":"A secondary progressive clinical course is uncommon in neuromyelitis optica","volume":"68","author":"Wingerchuk","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102879_bib0029","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/jnnp-2016-314005","article-title":"Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease","volume":"88","author":"Jury\u0144czyk","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.msard.2021.102879_bib0030","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"MRI characteristics of neuromyelitis optica spectrum disorder: an international update","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102879_bib0031","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jamaneurol.2014.2137","article-title":"Short Myelitis Lesions in Aquaporin-4-IgG\u2013Positive Neuromyelitis Optica Spectrum Disorders","volume":"72","author":"Flanagan","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2021.102879_bib0032","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1177\/1352458513515085","article-title":"Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset","volume":"20","author":"Collongues","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2021.102879_bib0033","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1136\/jnnp-2017-317566","article-title":"Worldwide prevalence of neuromyelitis optica spectrum disorders","volume":"89","author":"Mori","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.msard.2021.102879_bib0034","article-title":"Incidence of AQP4-IgG seropositive neuromyelitis optica spectrum disorders in the Netherlands: about one in a million","volume":"2","author":"Dani\u00eblle van Pelt","year":"2016","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10.1016\/j.msard.2021.102879_bib0035","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/1352458508102085","article-title":"Is neuromyelitis optica associated with human leukocyte antigen?","volume":"15","author":"Z\u00e9phir","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2021.102879_bib0036","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jneuroim.2010.11.004","article-title":"HLA-DPB1 * 0501 is associated with susceptibility to anti-aquaporin-4 antibodies positive neuromyelitis optica in Southern Han Chinese","volume":"233","author":"Wang","year":"2011","journal-title":"J Neuroimmunol"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821001462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821001462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:51:57Z","timestamp":1761900717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821001462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":36,"alternative-id":["S2211034821001462"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.102879","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population-based head-to-head comparison of the clinical characteristics and epidemiology of AQP4 antibody-positive NMOSD between two European countries","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.102879","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102879"}}